CClinicalTrials.gg
Sign In
CompletedNCT03978143Updated Nov 15, 2019

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

A Phase 1 interventional study of Treatment A and Treatment B in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-15.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2019, 6 years 11 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of the study is to estimate the relative bioavailability and palatability of 2 new crizotinib formulations to the commercially available crizotinib formulated capsule at a 250 mg dose administered under fasted conditions in adult healthy participants. Additionally, this study aims to assess the safety and tolerability of crizotinib 250 mg single dose in 4 formulations when given fasted, with high fat meal, or with a proton pump inhibitor in healthy participants. Finally, this study will explore the effect of food or proton pump inhibitor on the pharmacokinetics of the 2 new crizotinib formulations.

We hypothesize 1 of the 2 new crizotinib formulations will have improved relative bioavailability and palatability than the formulated capsule under fasted or fed conditions with or without a proton pump inhibitor.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Adult
  • Bioavailability
  • Crizotinib
  • Drug Interactions
  • Esomeprazole
  • Humans
  • Microsphere
  • Pharmacokinetics
  • Safety
  • Taste
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.

Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
  • Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy, gastric or intestinal bypass surgery, cholecystectomy).
  • Any condition possibly affecting the ability to taste (eg, dysgeusia, respiratory infection).
  • History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.
  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory test abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of crizotinib.
  • Participants with history of known sensitivity to esomeprazole or substituted benzimidazoles.
  • Previous administration with an investigational product within 30 days or 5 half-lives preceding the first dose of crizotinib (whichever is longer).
  • A positive urine drug test or cotinine test.
  • Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  • Baseline 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, QT interval corrected using the Fridericia's method [QTcF] >450 msec, complete left bundle branch block [LBBB], signs of an acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias). If QTcF exceeds 450 msec, or the QRS complex exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS complex values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
  • Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary: Aspartate aminotransferase (AST) or ALT level ≥1.5 × upper limit of normal (ULN); Total bilirubin (TBili) level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN; Estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2 (See Appendix 10.2 for calculation method).
  • Male participants who are unwilling or unable to comply with the contraception requirement listed in Section 10.4.1.

  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer,

    1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).

  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Participants who currently smoke.
  • Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Other
    Sequence 1

    Receive treatments in the following order from Periods 1-6: A, B, C, D, E, G

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D · Drug: Treatment E · Drug: Treatment G

  • Other
    Sequence 2

    Receive treatments in the following order from Periods 1-6: A, C, B, D, E, G

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D · Drug: Treatment E · Drug: Treatment G

  • Other
    Sequence 3

    Receive treatments in the following order from Periods 1-6: B, A, C, D, E, G

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D · Drug: Treatment E · Drug: Treatment G

  • Other
    Sequence 4

    Receive treatments in the following order from Periods 1-6: B, C, A, D, F, H

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D · Drug: Treatment F · Drug: Treatment H

  • Other
    Sequence 5

    Receive treatments in the following order from Periods 1-6: C, A, B, D, F, H

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D · Drug: Treatment F · Drug: Treatment H

  • Other
    Sequence 6

    Receive treatments in the following order from Periods 1-6: C, B, A, D, F, H

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D · Drug: Treatment F · Drug: Treatment H

Interventions

  • DrugTreatment A

    Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

  • DrugTreatment B

    A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.

  • DrugTreatment C

    A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

  • DrugTreatment D

    A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

  • DrugTreatment E

    250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.

  • DrugTreatment F

    250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.

  • DrugTreatment G

    40 mg esomeprazole will be administered 1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

  • DrugTreatment H

    40 mg esomeprazole will be administered 1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 12, 24, 48, and 96 hours post-dose in Periods 1, 2, 3, 5, and 6.

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 12, 24, 48, and 96 hours post-dose in Periods 1, 2, 3, 5, and 6.

  3. Maximum Observed Plasma Concentration (Cmax)

    Maximum observed plasma concentration.

    Time frame: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 12, 24, 48, and 96 hours post-dose in Periods 1, 2, 3, 5, and 6.

  4. Number of subjects reporting overall liking of drug formulation

    Overall liking assesses the degree that a participant likes a drug formulation based on sensory attributes experienced by the participant after tasting a product. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

  5. Number of subjects reporting bitterness of drug formulation

    Bitterness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

  6. Number of subjects reporting mouth feel from drug formulation

    Mouth feel assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

  7. Number of subjects reporting tongue/mouth burn from drug formulation

    Tongue/mouth burn assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

  8. Number of subjects reporting throat burn from drug formulation

    Throat burn assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

  9. Percentage of subjects reporting overall liking of drug formulation

    Overall liking assesses the degree that a participant likes a drug formulation based on sensory attributes experienced by the participant after tasting a product. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

  10. Percentage of subjects reporting bitterness of drug formulation

    Bitterness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

  11. Percentage of subjects reporting mouth feel from drug formulation

    Mouth feel assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

  12. Percentage of subjects reporting tongue/mouth burn from drug formulation

    Tongue/mouth burn assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

  13. Percentage of subjects reporting throat burn from drug formulation

    Throat burn assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.

    Time frame: 1 (immediately after dosing), 5, 10, and 20 minutes after crizotinib administration in Treatments A, B and D.

07

Study locations

1 site
  • Pfizer New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03978143
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 6, 2019
Start date
Jun 12, 2019
Primary completion
Oct 17, 2019
Completion
Oct 17, 2019
Last update
Nov 15, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Pfizer

Start the discussion